Gordian Bio Unveils $60M Platform for Age-Related Disease Therapies

Apr 28, 2024, 03:23 PM

Gordian Bio, co-founded by Martin Jensen and Leport five years ago, has officially launched its innovative platform designed to accelerate the development of therapies for age-related diseases. The biotech startup, which unveiled its platform yesterday, has raised $60 million to support its high-throughput in vivo screening platform. This platform allows for the simultaneous testing of hundreds of gene therapies in animal models that closely mirror human biology. The company aims to produce more effective therapies more quickly and cost-effectively while using fewer animals.